united therapeutics

Insiders may buy shares of a company because they believe its stock price will move higher and want to profit from this anticipated rise. Sell-offs might provide an opportunity for insiders who have faith in a company to snatch up shares. Below are some stocks that have recently seen insider buying...

Oppenheimer is out with its report today on United Therapeutics (NASDAQ: UTHR), maintaining Outperform. In a note to clients, Oppenheimer writes, "We believe UTHR's revenue/EPS growth rate will substantially exceed almost all mid- and large-cap biotech peers' in 2010-2013. We expect the robust...

According to Auriga, United Therapeutics (NASDAQ: UTHR) reported preliminary top-line results from the closely watched FREEDOM-M trial. Auriga said that the primary endpoint was change in 6 Minute Walk Distance (6MWD) at 12 weeks for 228 patients that received 0.25 mg dose increments. “Results...

Jefferies is maintaining its Hold rating on shares of United Therapeutics Corp. (NASDAQ: UTHR). “Lower-than-expected 6MWD improvement with oral treprostinil in FREEDOMM, albeit hitting statistical significance, places pressure on second Ph3 study (FREEDOM-C2; data in Sept),” Jefferies writes. “We...

Citadel Securities, which downgraded shares of United Therapeutics Corp. (NASDAQ: UTHR), is providing some color on the stock. “We are downgrading UTHR shares to Neutral from Add following the announcement of disappointing data from the FREEDOM-M study evaluating oral treprostinil monotherapy in...

Citadel Securities has downgraded United Therapeutics Corporation (NASDAQ: UTHR) from Add to Neutral and has lowered the price target from $70 to $60.

Citi is out with its report today on United Therapeutics (NASDAQ: UTHR), upgrading UTHR from Neutral to Add. In a note to clients, Citi writes, "We are upgrading UTHR to Add (from Neutral) and raising our 12-month price target to $70 (from $65) based on our expectations for a positive outcome from...

In a report released today, Collins Stewart commented on United Therapeutics (NASDAQ: UTHR). In the report, Collins Stewart was positive in its assessment of the company. Collins Stewart writes, “Our physician feedback suggests that the introduction of smaller doses has dramatically improved...

Oppenheimer is out with its report today on United Therapeutics (NASDAQ: UTHR), maintaining Outperform. In a note to clients, Oppenheimer writes, "We believe UTHR's revenue/EPS growth rate will substantially exceed almost all mid- and large-cap biotech peers' in 2010-2013. We expect the robust...

According to Auriga, United Therapeutics (NASDAQ: UTHR) oral Remodulin is a potentially transformative drug for both Pulmonary Arterial Hypertension (PAH) patients and UTHR. Auriga reported that it believes an oral formulation enables prostacyclin therapy to move into the front-line setting,...

JP Morgan has raised the price target on United Therapeutics Corporation (NASDAQ: UTHR) from $75 to $85 and maintains its Overweight rating.